Mitochondria-targeted tetrapeptide
SS-31 (elamipretide)
Binds cardiolipin on the inner membrane, stabilizing electron-transport supercomplexes in experimental and some clinical-development settings.
Primary Mechanism of Action
Clinical / Scientific
SS-31 (elamipretide) associates with cardiolipin, reducing electron leak and improving ATP synthesis efficiency in dysfunctional in models. Clinical programmes exist for selected and cardiorenal conditions; approval status is indication-specific and limited.
Pathway Targets
Cardiolipin / inner membrane
Scientific explanation
Stabilization of cristae and ETC supercomplexes.
Oxidative stress signalling
Scientific explanation
Reduced ROS leak in models of failure.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: Cardiolipin / inner membrane → Oxidative stress signalling
Mechanistically Relevant Repurposed & Adjunctive Applications
Mitochondrial disease / heart-failure development
InvestigationalMechanistic rationale
Elamipretide has been in clinical development; it is not a general anti-aging approval.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| Cardiolipin | Binding / membrane stabilization | ETC efficiency | Investigational |
In Plain Language
SS-31 sticks to cardiolipin, a special fat in the inner wall, helping the energy chain stay organized when are damaged — in research and limited development settings.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
Oxidative stress signalling
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.